1/69
Vocabulary practice flashcards covering fundamental pharmacogenomics, adverse drug reactions, medication error categorization, error prevention models, and medication adherence strategies from Larkin University's PA 5111 course.
Pharmacogenomics
The science of examining inherited variations in genes that determine a person's response to a drug, integrating genetics and pharmacology to design treatments with improved efficacy and reduced adverse reactions.
Nucleotide
A subunit of nucleic acids (DNA and RNA) consisting of a nitrogen base (adenine, guanine, thymine, cytosine, or uracil), a five-carbon sugar (deoxyribose or ribose), and a phosphate group.
Chromosome
A tightly packed structure within the cell nucleus composed of DNA and proteins that contains genes; human cells contain 23 pairs.
Gene
A specific sequence of nucleotides that provides the instructions or recipe to code for a single protein, often termed the blueprint of life.
Allele
A specific variant or form of a gene; can be wild-type (most commonly occurring) or a variant form, designated with star-nomenclature such as *1, *2, or *3.
Genotype
The set of unique genes or allele combinations (e.g., CYP2C19 1/3) that determine a specific trait in an individual.
Phenotype
The observable outward trait or clinical manifestation of a genotype, such as hair color, sickle cell disease, or fast versus slow drug metabolism.
Haplotype
A group of genes or DNA variations located on the same chromosome that are inherited together from a single parent (e.g., VKORC1 haplotypes in warfarin response).
Single Nucleotide Polymorphism (SNP)
The most common genetic alteration in DNA, characterized by a single base-pair change (e.g., C replaced by G), accounting for the majority of individual variability in drug response.
Structural Variation (SV)
Large-scale genetic polymorphisms involving substantial segments of DNA, such as gene duplications that can lead to ultra-rapid metabolism.

Autosomal Dominant Inheritance
A pattern of inheritance where a single copy of a mutated allele from one parent produces the affected phenotype, resulting in a 50% chance of offspring being affected.

Autosomal Recessive Inheritance
A pattern of inheritance requiring two copies of a mutated gene (one from each parent) to produce the phenotype, yielding a 25% chance of an affected child and a 50% chance of a carrier child.
Poor Metabolizer (PM)
An individual with significantly reduced or absent drug-metabolizing enzyme activity, causing elevated active drug levels or failure to convert prodrugs to active metabolites.
Ultra-rapid Metabolizer (UM)
An individual with abnormally elevated enzyme activity (often due to gene duplication), causing rapid drug clearance or rapid over-conversion of a prodrug to its active form.

Genetic Variability in Metabolism (CYP450)
Variations in enzyme expression where deleted genes produce no enzyme, single genes yield normal/unstable enzymes, and duplicated genes result in higher enzyme levels.
HLA-B*1502
A human leukocyte antigen allele prevalent in Asian populations that increases the risk of Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) 113.4-fold when exposed to carbamazepine.
HLA-B*5701
An allele strongly associated with fatal hypersensitivity reactions to the antiretroviral abacavir; screening is required before initiation and use is contraindicated if positive.
HLA-B*5801
An allele linked to an elevated risk of severe Stevens-Johnson syndrome upon allopurinol exposure, particularly in patients of Korean, Han Chinese, or Thai ancestry.
CYP2C19 Polymorphism (Clopidogrel)
A genetic variation affecting clopidogrel bioactivation; patients carrying loss-of-function *2 or *3 alleles cannot adequately form the active antiplatelet metabolite, increasing cardiovascular risk.
CYP2D6 Polymorphism (Codeine)
Variation in the enzyme converting codeine to morphine; ultra-rapid metabolizers face life-threatening opioid toxicity, leading to FDA contraindications for children post-tonsillectomy/adenoidectomy.
VKORC1 and CYP2C9 Variants (Warfarin)
Polymorphisms (CYP2C92, CYP2C93, and VKORC1 G > A) that decrease warfarin clearance and increase target sensitivity, necessitating lower initial dosages to prevent bleeding.
HER2 Testing (Trastuzumab)
A pharmacogenomic test required to identify overexpression of human epidermal growth factor receptor 2; trastuzumab is ineffective if tumor status is HER2 negative.
KRAS Mutation Testing (Cetuximab)
Diagnostic testing for colorectal cancer where only KRAS wild-type (mutation-negative) patients respond to EGFR inhibitors like cetuximab.
DPD Deficiency
A dihydropyrimidine dehydrogenase deficiency that severely impairs clearance of capecitabine and fluorouracil, precipitating fatal hematologic, gastrointestinal, and neurotoxicities.
Thiopurine Methyltransferase (TPMT)
An enzyme responsible for metabolizing azathioprine; low or absent activity dramatically increases bone marrow toxicity, resulting in life-threatening myelosuppression.
Adverse Drug Reaction (ADR)
Any unintended, noxious, or harmful pharmacologic effect of a drug that occurs when the medication is administered correctly at recommended dosages.
Medication Error
Any preventable event that may cause or lead to inappropriate medication use or patient harm while the medication is in the control of the healthcare professional, patient, or consumer.
Type A Reaction
A predictable, dose-dependent adverse drug reaction related to the known pharmacology of the drug, accounting for approximately 80% of all ADRs (e.g., orthostatic hypotension from doxazosin).
Type B Reaction
An unpredictable, dose-independent adverse drug reaction influenced by patient-specific factors, comprising drug allergies, pseudoallergic reactions, intolerances, and idiosyncratic responses.
Drug Intolerance
A predictable, non-immune adverse reaction occurring at subtherapeutic or normal therapeutic doses that is not life-threatening (e.g., nausea from codeine, diarrhea from metformin).
Pseudoallergic Reaction
A non-immune-mediated reaction that mimics an allergic response through direct histamine release without specific antibody activation (e.g., itching from opioids or vancomycin infusion reaction).
Type I Hypersensitivity Reaction
An immediate, IgE-mediated allergic reaction occurring within seconds to minutes of re-exposure, where cross-linking on mast cells and basophils triggers histamine release.
Type II Hypersensitivity Reaction
A cytotoxic reaction mediated by IgG or IgM antibodies directed against cell-surface bound drugs, leading to complement-mediated lysis (e.g., penicillin-induced hemolytic anemia, HIT).
Type III Hypersensitivity Reaction
An immune-complex-mediated reaction occurring 1 to 3 weeks after exposure, characterized by antigen-antibody complexes depositing in tissues and inciting inflammation (e.g., serum sickness, drug-induced lupus).
Type IV Hypersensitivity Reaction
A delayed cell-mediated immune response driven by T-lymphocytes rather than antibodies, presenting 48 hours to weeks after exposure (e.g., contact dermatitis, SJS/TEN, DRESS).
Urticaria
A vascular skin reaction characterized by pruritic, raised red or pink patches (wheals/hives) of varied shapes and sizes.
Angioedema
Submucosal and deep dermal swelling caused by localized edema in cutaneous, mucosal, and submucosal tissue, often affecting the lips, tongue, and throat.
Boxed Warning
The FDA's strongest warning category, marked by a black border around the text, indicating a significant risk of death or permanent disability associated with a medication.
Contraindication
A clinical situation or patient characteristic where a medication must not be administered because the risks clearly outweigh any possible therapeutic benefit.
Risk Evaluation and Mitigation Strategies (REMS)
FDA-mandated safety programs developed by manufacturers to manage known serious risks, incorporating elements such as prescriber certification, registries, and monitoring (e.g., iPLEDGE for isotretinoin).
Medication Guide
An FDA-approved, non-technical patient handout detailing serious adverse effects, required by law to be dispensed with specific outpatient prescriptions and every refill.

Naranjo Scale
A validated 10-question causality assessment algorithm that scores the probability that an adverse event is drug-induced (>9 = definite, 5-8 = probable, 1-4 = possible, ≤0 = doubtful).
MedWatch
The FDA's voluntary safety reporting program for healthcare providers and consumers to submit reports of adverse events involving drugs, biologics, devices, and supplements to FAERS.
To Err is Human
The landmark 1999 Institute of Medicine (IOM) report highlighting the widespread prevalence and financial impact of medical errors, catalyzing national safety research and legislation.
Error of Execution
A medical error where a correct and planned action fails to be completed as intended.
Error of Planning
A medical error where an inappropriate or wrong plan was selected and carried out.
Error of Commission
A medical error characterized by taking the wrong action, such as administering penicillin to a patient with a documented penicillin allergy.
Error of Omission
A medical error characterized by failing to take an appropriate action, such as missing a scheduled drug dose or failing to order required laboratory monitoring.
Sentinel Event
An unexpected adverse event resulting in death, permanent harm, or severe temporary harm that requires immediate investigation and root cause analysis.
Close Call (Near Miss)
A medication-related event that had the capacity to cause patient harm but was intercepted or did not cause injury.

NCC MERP Index
A standardized categorization system classifying medication error severity from Category A (circumstances with capacity to cause error) through Category I (error resulting in patient death).
Computerized Physician Order Entry (CPOE)
An electronic prescribing system that directly enters medical orders to reduce illegible handwriting and transcription errors, demonstrated to reduce overall error rates by 48%.
Barcode Medication Administration (BCMA)
A bedside scanning safety technology that verifies the Five Rights of medication administration (right patient, drug, dose, time, and route) before dosing.

Tall Man Lettering
The practice of using capitalized typography for distinct syllables in look-alike and sound-alike generic drug names (e.g., buPROPion vs busPIRone) to prevent dispensing mix-ups.

Joint Commission "Do Not Use" List
A mandated list of error-prone abbreviations and notations (such as U, IU, QD, QOD, trailing zeros, lack of leading zeros, and MSO4) prohibited from medical records.
Medication Reconciliation
The formal process of compiling the most complete and accurate list of a patient's medications across transitions of care and comparing it against newly ordered therapy.

Swiss Cheese Model
A system safety model illustrating that harm occurs only when defensive barriers (prescriber, pharmacist, nurse checks) all simultaneously fail, allowing an error trajectory to reach the patient.
Root Cause Analysis (RCA)
A structured retrospective investigation conducted after an adverse or sentinel event to identify underlying systemic vulnerabilities rather than assign individual blame.
Failure Modes and Effects Analysis (FMEA)
A proactive, prospective risk-assessment technique carried out before implementing a new healthcare process to identify potential failure points and prevent errors.
Just Culture
A safety culture framework that distinguishes between human error (managed by system redesign), at-risk behavior, and reckless negligence, promoting accountability without fear of unjust punishment.
Medication Compliance
A traditional term denoting a passive process where the patient conforms to prescriber directions, placing responsibility and blame entirely on the patient for deviations.
Medication Adherence
The degree to which a patient's behavior corresponds with agreed-upon recommendations from a healthcare provider, emphasizing an active partnership and shared decision-making.
Intentional Non-adherence
An active decision-making process where a patient purposefully chooses to deviate from prescribed therapy due to beliefs, perceived side effects, low trust, or health fears.
Unintentional Non-adherence
A passive failure to adhere to medication regimens caused by forgetfulness, cognitive issues, physical limitations, lack of financial resources, or complex schedules.

Five Dimensions of Adherence
A World Health Organization framework categorizing adherence barriers into Social & Economic, Health Care System, Condition-Related, Therapy-Related, and Patient-Related factors.
Morisky Medication Adherence Scale (MMAS-8)
An 8-item self-report questionnaire assessing adherence behaviors, where a score of 8 indicates high adherence, 6 to 7 indicates medium adherence, and below 6 reflects low adherence.
SIMPLE Model
A multi-component adherence improvement strategy: Simplify regimen, Impart knowledge, Modify patient beliefs, Provide communication and trust, Leave the bias, and Evaluate adherence.

Stages of Change (Transtheoretical Model)
A behavioral readiness framework outlining progression through Precontemplation, Contemplation, Preparation, Action, and Maintenance, with Relapse viewed as a normal learning setback.
O.A.R.S.
The core communication skills of motivational interviewing: Open-ended questions, Affirmations, Reflective listening, and Summarizing.
Elicit-Provide-Elicit
A collaborative communication technique in which the provider asks permission and explores prior knowledge, provides new health information, and elicits the patient's understanding.